Affymetrix, Leica Microsystems enter worldwide collaboration on RNA ISH analysis

Affymetrix, Inc. (NASDAQ:AFFX) and Leica Microsystems are pleased to announce a world-wide collaboration that automates Affymetrix' QuantiGene® ViewRNA ISH Tissue Assay on the Leica BOND RX staining platform for research applications. This partnership provides researchers with a powerful automated everyday solution for drug-discovery, translational research, and the development of new companion diagnostic tests for personalized medicine by significantly reducing assay time for single-copy RNA in situ hybridization (ISH) analysis.

“We are excited by this partnership with Leica as it unlocks the true potential of single-copy RNA analysis and we believe it will accelerate the discovery of important new drugs and the validation of novel companion tests.”

The highly-sensitive QuantiGene® ViewRNA ISH Tissue Assay assists drug discovery and translation research by enabling researchers to measure RNA expression directly in a tissue section at single-copy sensitivity. Over one thousand standard probes are already available and it only takes a few days to produce a customized probe for a new gene target. The Leica BOND RX system automates the staining process bringing all the benefits of consistency, reduced labor, and speed. This means researchers can now have access to same-day assay completion and, with a standardized staining protocol, rapid set-up for any probe.

George Bers, Vice President and General Manager of Expression Business Unit - Panomics at Affymetrix states that: "We are excited by this partnership with Leica as it unlocks the true potential of single-copy RNA analysis and we believe it will accelerate the discovery of important new drugs and the validation of novel companion tests."

Arnd Kaldowski, President of Leica Biosystems, agrees saying "While medical science has created powerful new treatments that greatly enhance lives, there are still many disease states where we need to discover better treatments, or even cures. We are proud that this collaboration with Affymetrix can help in the discovery and development process by enabling researchers to reduce both the time and cost of research so that new treatments can be made available to patients sooner."

Affymetrix' QuantiGene® ViewRNA ISH Tissue Assay will be available for research applications in Q3 2012 on the research-optimized Leica BOND RX platform. An optimized QuantiGene® ViewRNA staining protocol will be pre-loaded onto the Leica BOND RX and a complete staining kit, including probes and all detection components, will be available from Affymetrix.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The crucial role of sleep in heart healing